24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS) Download PDF Post navigationPreviousPrevious post:FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®NextNext post:Update on clinical development programRelated PostsNew publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026Update on clinical development program16 April 2026FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®9 February 2026AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 204121 January 2026AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia7 January 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer29 January 2026
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 204121 January 2026
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia7 January 2026
